Document Detail

Hemodynamic effects of urapidil in patients with pulmonary hypertension. A comparative study with hydralazine.
MedLine Citation:
PMID:  3813189     Owner:  NLM     Status:  MEDLINE    
Vasodilator therapy for pulmonary hypertension ideally should cause a proportionately greater reduction of resistance in the pulmonary vascular bed than in the systemic circulation. This should limit the occurrence of systemic hypotension, which can complicate the use of most vasodilator drugs. Urapidil is a new vasodilator that acts by postsynaptic alpha 1-blockade while inhibiting the aortic pressure baroreceptor reflex and reducing central sympathetic tone. We investigated and compared the short-term effects of Urapidil and hydralazine in 10 patients suffering varying degrees of pulmonary hypertension. Each patient received either 0.35 mg/kg hydralazine or 0.75 mg/kg Urapidil intravenously on 2 sequential days in a randomized order. The main effect of Urapidil was to decrease the mean pulmonary artery pressure in all 10 patients from 44 +/- 4 to 37 +/- 3.5 mm Hg (p less than 0.001). After Urapidil infusion, the mean decrease of resistance in the pulmonary vascular bed (32%) exceeded that in the systemic circulation (25%). In contrast, pulmonary artery pressure remained unchanged with hydralazine, and predominant systemic vasodilation occurred: systemic vascular resistance decreased by 45%, whereas pulmonary vascular resistance decreased by 25%. Hydralazine markedly increased the cardiac index and induced tachycardia. Urapidil maintained the heart rate nearly constant and only slightly increased the cardiac index, thereby fostering the diastolic emptying of the pulmonary circulation. No significant change in arterial oxygenation occurred with either drug, although arterial oxygen partial pressure tended to increase with hydralazine. Urapidil may be a promising drug in the treatment of patients with pulmonary hypertension.
S Adnot; C Defouilloy; C Brun-Buisson; F Abrouk; J Piquet; F Lemaire
Related Documents :
10462369 - Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a...
6714289 - Haemodynamic evaluation of ibopamine in severe congestive heart failure.
3278589 - Hypoxic vs septic pulmonary hypertension. selective role of thromboxane mediation.
3921279 - Dose requirements and hemodynamic effects of transdermal nitroglycerin compared with pl...
2494909 - Prostaglandin e1 and nitroglycerin reduce pulmonary capillary pressure but worsen venti...
8896159 - Fluid resuscitation with haemaccel vs. human albumin following coronary artery bypass g...
17171949 - Rapid-sequence induction technique in patients with severe ventricular dysfunction.
8573799 - Development of an electrohydraulic total artificial heart at the national cardiovascula...
17960059 - Location not quantity of blood pressure measurements predicts mortality in hemodialysis...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The American review of respiratory disease     Volume:  135     ISSN:  0003-0805     ISO Abbreviation:  Am. Rev. Respir. Dis.     Publication Date:  1987 Feb 
Date Detail:
Created Date:  1987-03-11     Completed Date:  1987-03-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370523     Medline TA:  Am Rev Respir Dis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  288-93     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects
Cardiac Output / drug effects
Hemodynamics / drug effects*
Hydralazine / therapeutic use*
Hypertension, Pulmonary / drug therapy*,  physiopathology
Middle Aged
Piperazines / therapeutic use*
Pulmonary Artery / drug effects
Vascular Resistance / drug effects
Reg. No./Substance:
0/Piperazines; 34661-75-1/urapidil; 86-54-4/Hydralazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chest pain, shock, and pneumomediastinum in a previously healthy 56-year-old man.
Next Document:  Reduction of chronic hypoxic pulmonary hypertension in the rat by an inhibitor of collagen productio...